What is SLU-PP-332?
1. Selective Dopamine D2 Receptor Antagonist:
SLU-PP-332 specifically blocks dopamine D2 receptors without significantly affecting other dopamine receptor subtypes.2. Potential Application in Neurological Disorders:
Its antagonistic action on D2 receptors suggests potential use in treating conditions like:
- Parkinson’s Disease: To balance dopamine signaling when excessive receptor activity contributes to motor symptoms.
- Schizophrenia: To mitigate dopamine hyperactivity linked to psychotic symptoms.
3. Role in Dopamine Regulation:
By selectively targeting D2 receptors, it may help in managing the dopamine dysregulation observed in various brain disorders, affecting motor control, mood, and cognition.4. Research Compound:
SLU-PP-332 is primarily studied in a research context, offering insights into dopamine receptor functions and the development of targeted therapies.5. Non-Selective Impacts on Other Receptors:
Although selective for D2 receptors, understanding off-target effects or impacts on related systems is crucial for its development as a therapeutic agent.
This product is intended solely for laboratory research purposes. It is not suitable for consumption by humans, nor for medical, veterinary, or household purposes.
